Recent Quotes
View Full List
My Watchlist
Create Watchlist
Indicators
DJI
Nasdaq Composite
SPX
Gold
Crude Oil
Markets
Stocks
ETFs
Tools
Markets:
Overview
News
Currencies
International
Treasuries
Ucb ADR
(OP:
UCBJY
)
138.87
UNCHANGED
Streaming Delayed Price
Updated: 3:59 PM EST, Dec 30, 2025
Add to My Watchlist
Quote
Overview
Detailed Quote
Charting
Historical Prices
News
All News
News Headlines
Press Releases
Research
Quarterly Reports
Insider Filings
Other Filings
Price and Volume
Detailed Quote
Volume
0
Open
138.87
Bid (Size)
N/A (0)
Ask (Size)
N/A (0)
Prev. Close
138.87
Today's Range
138.87 - 138.87
52wk Range
71.16 - 151.75
Shares Outstanding
N/A
Dividend Yield
N/A
Intraday
1 Week
1 Month
3 Month
1 Year
3 Year
5 Year
Top News
More News
RFK Jr. Sued By Eli Lilly, Amgen Over Drug Discount Program
↗
August 06, 2025
Eli Lilly and Amgen are suing HHS over 340B certifications, claiming ineligible clinics cost them millions in lost revenue.
Via
Benzinga
Topics
Lawsuit
Biogen, UCB Take A Leap In Lupus With Promising Phase 3 Results
↗
June 12, 2025
UCB and Biogen's lupus candidate showed strong Phase 3 results, including fatigue improvement and higher remission versus standard care.
Via
Benzinga
Performance
YTD
+42.2%
+42.2%
1 Month
+0.3%
+0.3%
3 Month
-2.1%
-2.1%
6 Month
+41.3%
+41.3%
1 Year
+42.0%
+42.0%
More News
Read More
Protagonist/Johnson & Johnson Partnered Drug Shows Significant Skin Clearance In Pivotal Psoriasis Study
↗
May 09, 2025
Via
Benzinga
Pharma Industry Faces Jitters As Trump Hints At Historic Tariffs, BofA Outlines Probable Timeline
↗
April 09, 2025
Via
Benzinga
Topics
Government
Supply Chain
World Trade
UCB's Rare Childhood Epilepsy Drug Scores FDA Approval
↗
March 28, 2022
Via
Benzinga
Pharmaceutical Firms Say UK Investment Is 'Unlikely' Unless Payment Levy Is Adressed
↗
March 21, 2025
Via
Benzinga
Europe-Based UCB's Bimzelx Data Reveals Sustained Skin Clearance In Inflammatory Skin Disorders
↗
March 07, 2025
Via
Benzinga
Biogen Gains Momentum With Positive Lupus Drug Results, Analyst Sees Modest Valuation Upside
↗
November 20, 2024
Via
Benzinga
FDA Approves UCB's Psoriasis Drug For Expanded Use In Painful Inflammatory Skin Disease
↗
November 20, 2024
Via
Benzinga
Biogen/UCB Partnered Autoimmune Disease Candidate Hits Primary Goal In Late-Stage Study, Sets Stage Another Pivotal Trial
↗
September 24, 2024
Via
Benzinga
Longboard Pharmaceuticals Boasts High-Value Epilepsy Assets, Analyst Initiates Coverage
↗
September 10, 2024
Via
Benzinga
Week In Review: UCB Sells China Drug Portfolio To CBC For $680 Million
↗
August 31, 2024
Via
Talk Markets
Johnson & Johnson Seeks FDA Approval For Muscle Weakness Drug And Gears Up Showdown With Argenx and UCB
↗
August 29, 2024
Via
Benzinga
Belgium-Based Pharma Firm UCB To Offload China Neurology, Allergy Business For $680M To Asset Management Companies
↗
August 26, 2024
Via
Benzinga
There's Optimism Around Longboard Pharmaceuticals' Anti-Seizure Candidate: Analyst Boosts Price Target
↗
January 02, 2024
Via
Benzinga
Dianthus' Monoclonal Antibody On Promising Pathway To Gaining The Upper Hand - Analyst
↗
September 28, 2023
Via
Benzinga
Skin Disease Focused MoonLake Immunotherapeutics Poised To Outshine Rivals, Analyst Asserts
↗
August 31, 2023
Via
Benzinga
FDA Approves Rystiggo: The Only Treatment for Two Most Common Subtypes of Generalized Myasthenia Gravis in Adults
↗
June 27, 2023
Via
Benzinga
Cantor On MoonLake Immunotherapeutics - Initiates On Inexpensive Valuation, Strong Catalyst Path
↗
February 14, 2023
Via
Benzinga
The Week Ahead In Biotech (May 30-June 4): FDA Decision For Eton's Partnered Epilepsy Drug, ASCO Conference Gets Underway And More
↗
May 30, 2022
Via
Benzinga
Biogen-Xbrane Enter License Agreement For Cimzia Referenced Biosimilar, Xcimzane
↗
February 08, 2022
Via
Benzinga
The Week Ahead In Biotech (Jan. 23-29): Roche, Azurity FDA Decisions, J&J, Vertex Earnings, & More
↗
January 23, 2022
Via
Talk Markets
The Week Ahead In Biotech (Jan 23-29): Roche, Azurity FDA Decisions, J&J, Vertex Earnings, Samsara Vision IPO And More
↗
January 23, 2022
Via
Benzinga
UCB's Bispecific Marks Phase 3 Win For Second Psoriatic Arthritis Study
↗
January 21, 2022
Via
Benzinga
ZGNX Stock: The $1.9B UCB Deal That Has Zogenix Shares Zooming Higher Today
↗
January 19, 2022
Via
InvestorPlace
Frequently Asked Questions
Is Ucb ADR publicly traded?
Yes, Ucb ADR is publicly traded.
What exchange does Ucb ADR trade on?
Ucb ADR trades on the OTC Traded
What is the ticker symbol for Ucb ADR?
The ticker symbol for Ucb ADR is UCBJY on the OTC Traded
What is the current price of Ucb ADR?
The current price of Ucb ADR is 138.87
When was Ucb ADR last traded?
The last trade of Ucb ADR was at 12/30/25 03:59 PM ET
Stock Quote API & Stock News API supplied by
www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the
Privacy Policy
and
Terms Of Service
.
© 2025 FinancialContent. All rights reserved.